140 results about "Tumor cell membrane" patented technology

The invention provides an engineered membrane coated nano drug delivery system and application thereof, and belongs to the technical field of nano biomedices.The drug delivery system comprises an inner core combined with a drug, the inner core is coated with a cell membrane, based on the nano drug loading technology and the membrane coating technology, DOX and SRF are loaded on mPDA mesoporous nanoparticles, and thyroid cancer synergistic killing nanoparticles mPDS are formed; the bionic drug delivery system is characterized in that mPDS is used as a target drug delivery system, mPDS is coated with a genetically engineered tumor cell membrane, a dual-targeting membrane-coated nano drug delivery system (mPDS-coated CAR-M) is obtained, and the bionic drug delivery system can penetrate through thyroid cancer in a targeted manner, gather in a focus and reduce side effects of chemotherapy; when near-infrared irradiation is carried out on local tumor, DOX and SRF in mPDS are released, the synergistic effect of photothermal therapy-chemotherapy-targeted therapy is achieved, and the thyroid cancer is killed synergistically.

The invention relates to the technical field of nano-drug presentation systems, in particular to a nanoparticle for synergistically promoting hepatoma ferroptosis based on mesoporous manganese dioxide, salazosulfapyridine and a tumor cell biological membrane as well as a preparation method and application of the nanoparticle. The nanoparticle in the scheme comprises mesoporous manganese dioxide which is modified with a tumor cell membrane on the surface and loaded with salazosulfapyridine. According to the technical scheme, the nanoparticles can effectively induce hepatoma cell ferroptosis through a multi-target strategy. The salazosulfapyridine and the mesoporous manganese dioxide have a synergistic effect to enhance the ferroptosis effect; the tumor cell biological membrane has homologous targeting property, so that the accumulation capacity of the nanoparticles in liver cancer tissues is remarkably improved; the nanoparticle provided by the invention not only can be used for treatment, but also can monitor the change in the treatment process in real time. According to the technical scheme, the technical problem that a nano-drug presentation system for effectively inducing ferroptosis aiming at multiple target spots is lacked in the prior art can be solved, and the technical scheme has important significance in improving the survival rate and the life quality of liver cancer patients.

The invention discloses a tumor whole cell wrapped by a metal-polyphenol nano coating as well as a preparation method and application thereof. The preparation method comprises the following steps: step 1, fully mixing a plant polyphenol solution and a tumor cell suspension; 2, adding a manganese ion-containing compound solution, and fully mixing; 3, adding a buffer solution into the solution obtained in the step 2, fully mixing, washing, and centrifugally separating to obtain tumor cells coated with coatings; the plant polyphenol and the manganese ions can be quickly assembled at room temperature, a compact nano coating is formed on a tumor cell membrane, and tumor cells are inactivated due to the wrapping of the nano coating, so that the safety of the vaccine is ensured; the nano coating can prevent any potential tumor antigen from being lost under physiological conditions; lipopolysaccharide is further modified, so that the formed LMP whole-cell vaccine can be promoted to be endocytosed by antigen presenting cells; the metal manganese ions can stimulate the STING pathway to enhance the anti-tumor effect while forming the structural coating.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

A method for preparing nanoparticles of triterpenoid small molecules co-assembled with Ce6 and copper ions wrapped in cancer cell membranes and its application. The present invention prepares a pure natural co-assembled nanotransmission system with new morphological characteristics and multiple biological activities - terpenoid compound and photosensitizer co-assembled nanoparticles. In the composite nanoassembly, triterpenoid compounds and photosensitizer Ce6 are assembled into nanoparticles, providing effective and safe chemotherapy and photodynamic therapy. Subsequently, Cu is complexed on the surface of the nanoparticles. 2+ , when Cu is introduced 2+ When activated, the reduced PDT effect caused by excessive glutathione in the tumor consuming reactive oxygen species can be counteracted. Furthermore, it can enhance CDT therapy through a Fenton-like catalytic reaction with overexpressed H₂O₂ at the tumor site. Finally, these molecules are encapsulated by the tumor cell membrane. By constructing CM@OABACe6 / CuNPs with homologous targeting, a triple synergistic platform for cancer treatment using PDT, chemotherapy, and CDT has been created.

The invention relates to rapamycin-loaded bionic nanoparticles as well as a preparation method and application thereof. The bionic nanoparticle loaded with the rapamycin comprises RZ NPs loaded with the rapamycin and a tumor cell membrane, the tumor cell membrane is coated with the RZ NPs loaded with the rapamycin; the rapamycin is modified in pores of the RZ NPs; and the RZ NPs has a crystal structure of ZIF8. The preparation method of the rapamycin-loaded bionic nano-particles comprises the following steps: preparing RZ NPs loaded with rapamycin, and modifying the RZ NPs by using a tumor cell membrane to prepare the RZM NPs. The RZM NPs provided by the invention has the capability of external irradiation sensitization on tumors, and due to the fact that rapamycin has potential influence possibility on cell cycles, tumor cells can be stagnated in a stage which is more sensitive to external irradiation, so that the radiotherapy effect is improved.

Disclosed are a metal-polyphenol nano-coating-wrapped tumor whole cell, a preparation method therefor, and use thereof. A plant polyphenol in the present invention and manganese ions can be rapidly assembled at room temperature to form a dense coating on the membrane of a tumor cell. The nano-coating wrapping inactivates the tumor cell, ensuring that the vaccine is safe. The nano-coating can prevent any potential tumor antigen from being lost under physiological conditions. The nano-coating is further modified with a lipopolysaccharide, which can promote the endocytosis of the formed whole-cell vaccine by antigen-presenting cells. While forming the structural coating, ions of the metal manganese can stimulate the STING pathway to enhance the anti-tumor effect.

The invention discloses a method for preparing a multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method, and relates to a preparation method of a nano-hydroxyapatite-based tumor vaccine. The invention aims to solve the problems of low antigen presentation efficiency of existing tumor vaccines and complex preparation process of nano vaccines based on tumor cell membranes. The preparation method comprises the following steps: 1, preparing small-particle-size calcium-based nanoparticles; and 2, synthesizing the HAP NV (at) DOX nano compound. The preparation method is used for preparing the multifunctional nano-hydroxyapatite-based tumor vaccine by a one-step method.

The present invention discloses a fluorescent probe and its preparation method and application. The structural formula of the fluorescent probe of the present invention is: ‑ Cl ‑ Br ‑ , I ‑ The fluorescent probe of the present invention can rapidly undergo a bioorthogonal shear reaction to specifically activate fluorescence at the tumor site, thereby improving the imaging specificity of the target site. Simultaneously, the bioorthogonal coupling group of the probe is used to undergo biocoupling with cells, allowing the probe to be anchored on tumor cell membrane glycoproteins for long-term fluorescence imaging. The probe is suitable for non-invasive detection of tumors and surgical resection of tumors.

The present invention belongs to the field of biological probe technology, and in particular relates to a small molecule probe HBAPE-Ac3ManNAz based on sugar metabolism labeling and its application in improving the targeting of platinum drugs. The present invention provides a small molecule probe HBAPE-Ac3ManNAz based on sugar metabolism labeling. The probe can selectively label tumor cells or tissues in vivo or in vitro as a metabolic precursor, and provide new targets for refractory tumors such as triple-negative breast cancer that lack specific targeting receptors; a pharmacodynamic molecule DBCO-PEG8-Oxp(IV) complex that reacts orthogonally with the probe is synthesized. The complex reacts with an azide tag marked on the tumor cell membrane through a bioorthogonal reaction, thereby improving the targeted transport ability of platinum drugs to tumors and reducing toxic side effects, providing a new theoretical basis for the targeted treatment of tumors in organisms.

The present application relates to a kind of chitosan derivatives, its preparation method and application, belong to biological medical polymer material technical field.The method includes under the action of first catalyst, N-(2-hydroxypropyl)-3-trimethylammonium chloride chitosan is dissolved in first solvent, second solvent containing n-hexanoic anhydride is added to the first solvent containing N-(2-hydroxypropyl)-3-trimethylammonium chloride chitosan and is reacted, obtains chitosan derivative.The preparation method of the present application is easy to obtain raw material, and reaction condition is mild;And the chitosan derivative obtained carries a large number of positive charge, can be combined to the surface of negative electric tumor cell membrane by electrostatic interaction, promotes the interaction between the hydrophobic part of chitosan derivative and cell membrane phospholipid hydrophobic chain, destroys cell membrane stability and finally causes membrane lysis to make tumor cell necrosis.

Disclosed herein is an anti-tumor pharmaceutical composition based on immune checkpoint blockade and use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride, and a T-cell enhancer, wherein the T-cell enhancer is at least one of vitamin E and thymosin. Through a series of in vitro and in vivo experiments, cannabidiol and paroxetine hydrochloride were first found to be capable of effectively reducing the expression of PD-L1 on the tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the ability of T cells to kill tumor cells. The T-cell enhancer added on this basis can further increase the quantity and activity of T cells, significantly increase the killing ability of T cells after immunosuppression is relieved, and greatly improve the anti-tumor effect of the drug. The components of the pharmaceutical composition used in the present invention, namely, cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin, can exert a synergistic effect and improve the anti-tumor effect.

The invention relates to a polypeptide for targeted destruction of lipid droplets and application of the polypeptide in preparation of antitumor drugs, and belongs to the technical field of biological drug manufacturing. In order to solve the problem that an existing anti-tumor drug aiming at tumor lipid droplets cannot effectively inhibit immune escape of tumor cells while destroying the lipid droplets, the invention provides a polypeptide for targeted destruction of the lipid droplets, and the polypeptide comprises a PLIN2 targeted peptide fragment, a self-assembly peptide fragment, an enzyme response peptide fragment and an HLA-E targeted peptide fragment which are connected in sequence. On the basis of a double-targeting strategy, the polypeptide for targeted destruction of the lipid droplets is constructed, and the polypeptide can target the PLIN2 protein on the surfaces of the lipid droplets; the self-assembled peptide fragment can form a nanofiber structure on the surface of the lipid droplet, the structure and function of the lipid droplet are destroyed, endoplasmic reticulum stress is caused, and tumor cell immunogenicity death is caused. The HLA-E targeting peptide fragment released by polypeptide digestion can specifically target HLA-E on a tumor cell membrane, block an NKG2A-HLA-E pathway, and effectively inhibit immune escape of tumor cells.

The application discloses a kind of for sensitizing lung cancer radiotherapy biomimetic nano delivery system and preparation method and application, it belongs to the field of biological medicine, wherein, biomimetic nano delivery system is core-shell structure, including core and the shell of the core outer layer being wrapped;Wherein, core is the lipid nanoparticle of therapeutic nucleic acid being loaded;Shell is tumor cell membrane vesicle;Therapeutic nucleic acid is the short hairpin RNA expression plasmid of targeted deubiquitinating enzyme CYLD gene.The application solves lung cancer radiotherapy resistance problem from mechanism, by therapeutic nucleic acid specific knockdown deubiquitinating enzyme CYLD gene, effectively blocks CYLD / NRP1 signal shaft, to reverse the metabolic reprogramming of tumor cell, significantly enhance its radiotherapy sensitivity, realize to the low-toxicity treatment of radiation resistance lung cancer.

The invention discloses a nuclide labeled cell membrane coated nano material as well as a preparation method and application thereof. The nuclide-labeled cell membrane-coated nano material is obtained by loading beta nuclide on a manganese-based monatomic nano enzyme coated with a tumor cell membrane, and the manganese-based monatomic nano enzyme has hollow mesopores. The invention also discloses an application of the nuclide labeled cell membrane coated nano material in preparation of a drug targeting carrier or a tumor treatment drug. The nuclide-labeled cell membrane-coated nano-material can be efficiently targeted to a tumor site, has self-cascade catalytic enzyme-like activity, and can effectively exert an anti-tumor effect.

The invention discloses a fusion membrane packaged gold-iron core-shell nano diagnosis and treatment preparation as well as a preparation method and application thereof. The preparation takes gold-iron core-shell nanoparticles as a core, and the surface of the gold-iron core-shell nanoparticles is coated with a biomimetic membrane formed by fusion of bacterial outer membrane vesicles and tumor cell membranes. The preparation method comprises the steps of synthesis of the gold-iron nano core, surface functionalization and self-assembly coating of the fusion membrane. The preparation can simultaneously exert photothermal therapy and ferroptosis induction effects under near-infrared light irradiation, effectively initiates tumor cell immunogenicity death, and cooperatively activates dendritic cells and enhances T cell immune response by means of a pathogen related molecular mode carried by the fusion membrane and a tumor related antigen. Experiments show that the preparation can significantly inhibit tumor growth and metastasis, induce long-acting anti-tumor immune memory, and provide a multi-mode synergistic nano platform for tumor immunotherapy.

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

The invention discloses a bionic hybrid nano regulator for enhancing cell copper death and a preparation method and application thereof, and belongs to the technical field of biomedical materials. The invention designs a bionic nano-platform which simultaneously loads a lactic acid regulator cyclostilbene Su 3118 and a copper ion carrier disulfiram DSF, and the bionic nano-platform is combined with hybrid macrophages and tumor cell membranes to construct a nano-regulator SCTDM. The nano regulator can exert multiple functions, including tumor targeting, in-situ photothermal therapy, lactic acid regulation and enhanced copper death. The nano regulator provided by the invention is simple and convenient to manufacture, is combined with in-situ photothermal therapy and lactic acid regulation and is used for enhancing cell death immunotherapy of copper death so as to eliminate primary tumors and delay relapse, and a technical support is provided for regulating immunity by enhancing copper-induced cell death through metabolic reprogramming.

An anti-tumor pharmaceutical composition based on immune checkpoint blocking and a use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride and a T cell enhancer, the T cell enhancer being at least one of vitamin E and thymosin. By means of a series of in vivo and in vitro experiments, it was found for the first time that cannabidiol and paroxetine hydrochloride can effectively reduce the expression of PD-L1 on a tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the effect of T cells in killing tumor cells. T cell enhancer added on this basis can further increase the number and activity of T cells and significantly enhance the killing ability of T cells after relief from immunosuppression, greatly improving the anti-tumor effect of a drug. The components cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin of the pharmaceutical composition can have a synergistic effect to improve the anti-tumor effect.

The invention discloses an anti-tumor pharmaceutical composition and application thereof, the pharmaceutical composition comprises cannabidiol and paroxetine hydrochloride, and the mass ratio of the cannabidiol to the paroxetine hydrochloride is (5: 1)-(20: 1). Research finds that cannabidiol and paroxetine hydrochloride can respectively reduce expression of PD-L1 on a tumor cell membrane through different mechanism ways, specifically, CBD promotes degradation of PD-L1 through a lysosome way; the PAR is used for promoting the degradation of the PD-L1 through a ubiquitin-proteasome way. Based on the discovery, the CBD and the PAR are further combined for use, and the result shows that compared with independent use of the CBD and the PAR, the combined use of the CBD and the PAR can play a synergistic anti-tumor role, and the CBD and the PAR have no obvious toxic and side effects and are relatively high in use safety.

The invention relates to the technical field of anti-tumor bionic nanomaterials, and discloses a preparation method and application of tumor-bacterial membrane chimeric nanoparticles, and the preparation method comprises the following steps: carrying out rotary evaporation on dimyristoyl phosphatidylcholine and cholesterol oleate to obtain an HDL rotary evaporation film; mixing the tumor cell membrane with the bacterial membrane to obtain a tumor-bacterial mixed membrane; pre-mixing apolipoprotein ApoA-1 with the tumor-bacteria mixed membrane, and adding the mixed solution into a container containing an HDL rotary evaporation membrane for hydration and reconstruction to obtain a crude suspension; and carrying out ultrafiltration purification on the crude suspension to obtain the tumor-bacterial membrane chimeric nanoparticles. The tumor cell membrane and the bacterial membrane are co-loaded on the high-density lipoprotein, so that the two membrane components can be co-delivered to the dendritic cells to induce maturation of the dendritic cells, are accumulated in tumors and drainage lymph nodes in vivo, activate CD8 + T cell response and have an inhibition effect on tumor growth.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

The invention discloses a tumor cell membrane modified polypeptide nano-carrier as well as a preparation method and application thereof. The preparation method of the carrier comprises the step of assembling a tumor cell membrane and polypeptide with opposite charges through an electrostatic adsorption effect to form the tumor cell membrane modified polypeptide nano-carrier. According to the tumor cell membrane modified polypeptide nano-carrier prepared by the invention, the membrane penetrating efficiency in tumor cells and immune cells can be obviously improved, and nucleic acid molecules and drug molecules can be effectively delivered to the tumor cells and the immune cells.

Disclosed herein is an anti-tumor pharmaceutical composition based on immune checkpoint blockade and use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride, and a T-cell enhancer, wherein the T-cell enhancer is at least one of vitamin E and thymosin. Through a series of in vitro and in vivo experiments, cannabidiol and paroxetine hydrochloride were first found to be capable of effectively reducing the expression of PD-L1 on the tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the ability of T cells to kill tumor cells. The T-cell enhancer added on this basis can further increase the quantity and activity of T cells, significantly increase the killing ability of T cells after immunosuppression is relieved, and greatly improve the anti-tumor effect of the drug. The components of the pharmaceutical composition used in the present invention, namely, cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin, can exert a synergistic effect and improve the anti-tumor effect.

The invention discloses preparation and application of a biomimetic cell membrane modified photosensitizer. A tumor cell membrane bionic camouflage technology is adopted, the surface of the photosensitizer nanoparticle is coated with the tumor cell membrane through repeated membrane extrusion or ultrasound, the photosensitizer-coated tumor cell membrane bionic nanoparticle is prepared, the preparation process is simple, the cost is low, and a complex synthesis process is not needed. The bionic nanoparticle disclosed by the invention has the functions of homologous targeting and immune escape, and can realize near-infrared two-region imaging. In addition, the bionic nanoparticles can kill tumor cells through photo-thermal and photodynamic effects, and have the advantages of good curative effect and low toxic and side effects.

The embodiment of the invention discloses a method for screening a tumor immune checkpoint inhibitor based on electrochemical luminescence sensing. According to the invention, an electrochemiluminescence sensor is established, and resonance energy transfer between luminol (an electrochemiluminescence donor) and a PD-L1-targeting metal cluster (an electrochemiluminescence receptor) is utilized; the electrochemical luminescence sensor capable of rapidly, sensitively, simply, conveniently and quantitatively analyzing the equilibrium dissociation constant between the non-antibody immune checkpoint inhibitor and the PD-L1 expressed on the tumor cell membrane at low cost is established. The efficiency of blocking the PD-1 / PD-L1 by the inhibitor is evaluated through quantitative analysis of the constant, so that the potential non-antibody immune checkpoint inhibitor is effectively screened.

According to the application of the inhibitor in preparation of the medicine for treating solid tumor cancers, NMT1 activity is blocked, myristicylation of CHP1 is reduced, combination of CHP1 and PD-L1 is interfered, and finally localization of PD-L1 on tumor cell membranes is reduced. The up-regulation of the NMT1 under the hypoxia condition and the regulation effect of the NMT1 on PD-L1 membrane localization are verified through various research and analysis means such as bioinformatics analysis and clinical case review as well as cell and animal levels, the key effect of the NMT1 in treatment of hypoxia-related cancers is disclosed for the first time, and the NMT1 is used as a core target of a combined therapy and is used for treating the hypoxia-related cancers. And a new means is provided for cancer immunotherapy and development and preparation of cancer drugs.

An anti-tumor pharmaceutical composition based on immune checkpoint blocking and a use thereof. The anti-tumor pharmaceutical composition comprises: paroxetine hydrochloride and a T cell enhancer, the T cell enhancer being at least one of vitamin E and thymosin. By means of a series of in vivo and in vitro experiments, it was found for the first time that cannabidiol and paroxetine hydrochloride can effectively reduce the expression of PD-L1 on a tumor cell membrane, thereby blocking the PD-1 / PD-L1 signaling pathway and enhancing the effect of T cells in killing tumor cells. T cell enhancer added on this basis can further increase the number and activity of T cells and significantly enhance the killing ability of T cells after relief from immunosuppression, greatly improving the anti-tumor effect of a drug. The components cannabidiol, paroxetine hydrochloride, and vitamin E+thymosin of the pharmaceutical composition can have a synergistic effect to improve the anti-tumor effect.